Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Disparities

Topic: Amyloid, tau and blood-test diagnosis

Alzheimer's disease (AD) is the most frequent cause of dementia, where the abnormal accumulation of beta-amyloid (Aβ) and tau lead to neurodegeneration as well as loss of cognitive, behavioral, and functional abilities. The present review analyzes AD from a cross-cultural neuropsychological perspective, looking at differences in culture-associated variables, neuropsychological test performance and biomarkers across ethnic and racial groups. Studies have found significant effects of culture, preferred language, country of origin, race, and ethnicity on cognitive test performance, although the definition of those grouping terms varies across studies. Together, with the substantial underrepresentation of minority groups in research, the inconsistent classification might conduce to an inaccuratte diagnosis that often results from biases in testing procedures that favor the group to which test developers belong. These biases persist even after adjusting for variables related to disadvantageous societal conditions, such as low level of education, unfavorable socioeconomic status, health care access, or psychological stressors. All too frequently, educational level is confounded with culture. Minorities often have lower educational attainment and lower quality of education, causing differences in test results that are then attributed to culture. Higher levels of education are also associated with increased cognitive reserve, a protective factor against cognitive decline in the presence of neurodegeneration. Biomarker research suggests there might be significant differences in specific biomarker profiles for each ethnicity/race in need of accurate cultural definitions to adequately predict risk and disease progression across ethnic/racial groups. Overall, this review highlights the need for diversity in all domains of AD research that lack inclusion and the collection of relevant information from these groups.

Key findings

Why it matters

This review finds that culture, preferred language, country of origin, race and ethnicity all affect scores on memory and thinking tests. It says testing procedures can favour the group the tests were developed in, and that this bias persists even after adjusting for education, income, health-care access and stress, which can lead to inaccurate diagnosis. It also notes that lower education is often mistaken for a cultural difference, and that biomarker profiles may differ between groups, so it calls for more diverse research. It is a review, not a trial, and reports no treatment.

Study details

How this study scored 48/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multi-centre collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 46 of the 96 points it could be judged on, which is 48 of 100. Total 48 of 100.46 of the 96 points we could judge = 48 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 46 of the 96 points we could judge it on, which is 48 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics)
Journal's citation record 2 / 4 Neurotherapeutics: journal h-index 156 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 140 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 23.3 citations a year over 6 year(s) since 2022
Impact for its field and year 4 / 6 Cited 17.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 11 other studies in this library
Still being cited 3 / 4 Cited 105 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Layaly Shihadeh holds only 5 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Florida Atlantic University: institution h-index 410 (OpenAlex)
Multi-centre collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 35347644)
Free to read 2 / 2 Free to read
Points 46 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 46 of the 96 points we could judge it on is 48 out of 100.
Total 48 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Rosselli, M., Uribe, IV., Ahne, E., & Shihadeh, L. (2022). Culture, Ethnicity, and Level of Education in Alzheimer's Disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. https://doi.org/10.1007/s13311-022-01193-z

Vancouver

Rosselli M, Uribe IV, Ahne E, Shihadeh L. Culture, Ethnicity, and Level of Education in Alzheimer's Disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2022. doi:10.1007/s13311-022-01193-z. PMID: 35347644.

BibTeX

@article{rosselli2022-35347644,
  author  = {Rosselli, M. and Uribe, IV. and Ahne, E. and Shihadeh, L.},
  title   = {{Culture, Ethnicity, and Level of Education in Alzheimer's Disease}},
  journal = {Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics},
  year    = {2022},
  doi     = {10.1007/s13311-022-01193-z},
  pmid    = {35347644},
  url     = {https://doi.org/10.1007/s13311-022-01193-z}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.

Later studies that cite this one

11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Disparities

Also in Disparities

98 studies in the library are filed under Disparities with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Disparities hub.

Similar studies

More on Disparities

See all studies in Disparities →